Summit Therapeutics Inc. (SMMT)
NASDAQ
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
15.0752 wk Range
12.07Overview - SMMT - Summit Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
11.75B
P/E (Trailing)
25.02
P/E (Forward)
-13.24
PEG Ratio
-0.39
Price / Book
19.60
EV / EBITDA
-13.43
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-101.61%
Return on Equity
-192.50%
Ownership
Shares Outstanding
793.12M
Float
153.87M
Short % of Shares Outstanding
26.29%
Held by Insiders
80.87%
Held by Institutions
17.60%
Price stats
Beta
-1.51
50-Day Avg
15.71
200-Day Avg
16.29
Dividends
Payout Ratio
0.00%
Analyst Consensus
17 analysts
Average price target
$ 28.62Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SMMT - Summit Therapeutics Inc.
Peers - SMMT - Summit Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SMMTNASDAQSummit Therapeutics Inc.12.62BMarket Cap-21.04%52-week change25.02P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - SMMT - Summit Therapeutics Inc.
About
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
